Drug intelligence / Profile preview

SOB-102

Development stage: Unknown
Lead developer: Shine-On Biomedical
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

SOB-102 is an exosome-based investigational therapy developed by Shine-On BioMedical. It is currently in the discovery phase and has not yet entered clinical trials. The drug is being explored for use in neoplasms (cancers) and nervous system diseases, with a specific active indication for glioblastoma multiforme. Detailed information about its mechanism of action, molecular targets, or additional pharmacological properties has not been disclosed publicly as of the latest available update[1][2].

Targets

HLA-G (Human leukocyte antigen G)

Beyond the preview

Go deeper on SOB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOB-102.

Explore the full profile